NAT2 slow acetylator function as a risk indicator for age-related cataract formation

Pharmacogenetics

Volumn 13, Issue 5, 2003, Pages 285-289

  Meyer, David ^a,c   Parkin, Donald P ^a   Seifart, Heine I ^a   Maritz, J Stefan ^b   Engelbrecht, Albertus H ^a   Werely, Cedric J ^a   Van Helden, Paul D ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c Department of Ophthalmology ^*  (South Africa)

Author keywords

Acetylator status; Age; Cataracts

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CATARACT; CATARACTOGENESIS; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION MAPPING; RISK ASSESSMENT;

AGED; ARYLAMINE N-ACETYLTRANSFERASE; CATARACT; GENOTYPE; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 0038241109     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200305000-00008     Document Type: Article

References (52)

1. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5:1-17.
2. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989; 42:157-234.
3. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 1979; 29:71-79.
4. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2:842-846.
5. Risch A, Wallace DM, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995; 4:231-236.
6. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56:3915-3925.
7. Okkels H, Sigsgaard T, Wolf A and Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomark Prev 1997; 6:225-231.
8. Filiadis IF, Georgiou I, Alamanos Y, Kranas V, Giannakopoulos X, Lolis D. Genotypes of N-acetyltransferase 2 and risk of bladder cancer: a case-control study. J Urol 1999; 161:1672-1675.
9. Borlak JT, Harsamy V, Schneble H, Haegele KD. PNAT and CYP2D6 gene polymorphism in epileptic patients. Biochem Pharmacol 1994; 48:1717-1720.
10. Siegmind W, Fengler JD, Franke G, Zschiesche M, Eike O, Eike E, et al. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Br J Clin Pharmacol 1991; 32:467-472.
11. Baranova H, Canis M, Ivaschenko T, Albuisson E, Bothorishvilli R, Bararov V, et al. Possible involvement of arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 genes in the development of endometriosis. Mol Hum Reprod 1999; 5:636-641.
12. Longuemaux S, Delomenie C, Gallou C, Mejean A, Vincent-Viry MN, Bouvier R, et al. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res 1999; 59:2903-2908.
13. Hirvonen A, Pelin K, Tammilehto L, Karjalainen A, Mattson K, Linnainmaa K. Inherited GSTM 1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res 1995; 55:2981-2983.
14. Hirvonen A, Saarikoski ST, Linnainmaa K, Loskinen K, Husgafvel-Puriainen K, Mattson K, et al. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst 1996; 88:1853-1856.
15. Morita S, Yano M, Tsujinaka T, Ogawa A, Taniguchi M, Kaneko K, et al. Association between genetic polymorphisms of glutathione S-transferase P1 and N-acetyltransferase 2 and susceptibility to squamous cell carcinoma of the esophagus. Int J Cancer 1998; 79:517-520.
16. Wikman H, Piirila P, Kaaria K, Rosenburg C, Norppa H, Hirvonen A. Role of NAT1 and NAT2 polymorphisms in individual susceptibility to isocyanate-induced asthma. First International Workshop on the Arylamine N-transferases, Queensland, Australia, 1998, Oct 22-24, (Abstract 12).
17. Zielinska E, Niewiarowski W, Bodalski J, Stanczyk A, Bolanowski W, Robowski G. Arylamine N-acetyltransferase gene mutations in children with allergic diseases. Clin Pharmacol Ther 1997; 62:635-642.
18. von Schmiedeberg S, Fritsche E, Ronnau AC, Specker C, Golka K, Richter-Hintz D, et al. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol 1999; 455:147-152.
19. Lang NP, Chu DZ, Hunter CF, Kendall DC, Flammang TJ, Kadlubar FF. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 1986; 121:1259-1261.
20. Ilett KF, David BM, Dethon P, Castleden WM, Kwa R. Acetylator phenotype in colorectal carcinoma. Cancer Res 1987; 47:1466-1469.
21. Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998; 19:37-41.
22. el-Yazigi A, Johansen K, Raines DA, Dossing M. N-Acetylation polymorphism and diabetes mellitus among Saudi Arabians. J Clin Pharmacol 1992; 32:905-910.
23. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acetyltransferase genotype as a susceptibility factor for lung cancer. Cancer Res. 1996; 56:3961-3966.
24. Pai P, Hindell P, Stevenson A, Mason H, Bell GM. Genetic variants of microsomal metabolism and susceptibility to hydrocarbon-associated glomerulonephritis. Q J Med 1997; 90:693-698.
25. Philip PA, Rogers HJ, Millis RR, Rubens Rd, Cartwright RA. Acetylator status and its relationship to breast cancer and other diseases of the breast. Eur J Cancer Clin Oncol 1987; 23:1701-1706.
26. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics 1999; 9:103-111.
27. Hadasova E, Brysova V, Kadlcakova E. N-Acetylation in healthy and diseased children. Eur J Clin Pharmacol 1990; 39:43-47.
28. Meyer D, Liebenberg P. Cataract Etiology. In: Agarwal S, Apple DJ, Agarwal A, Buratto L, Alio JL, Pandey SK, Agarwal A (editors). Textbook of Ophthalmology. New Delhi: Jaypee Brothers, 2002; pp. 1587-1619.
29. Shambhu DV, Palaniyandi SD, Ali HA. Oxygen radicals in the pathogenesis of cataracts. In: Nutritional and Environmental Influences on the Eye. London: CRC Press, 1999.
30. Marais JS. The Cape Coloured People: 1652 to 1932. Johannesburg: Witwatersrand University Press, 1957.
31. Parkin D.P, Vandenplas M, Donald PR, Vandenplas S, Botha FJH, Seifart HI, et al. Distribution of acetylator genotypes in the coloured population of the Western Cape region of South Africa. S Afr J Sci 1998; 94:404-406.
32. Parkin DP, Vandenplas S, Botha FJH, Vandenplas M, Seifart HI, van Helden PD, et al. Trimodality of isoniazid elimination: Phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155:1717-1722.
33. Stryjek-Kaminska D, Malczewski B, Kopec A, Rowinska-Marcinska K. Acetylator phenotypes in diabetes mellitus. Acta Diabetol Lett 1988; 25:41-48.
34. Meyer D, Maritz FJ, Liebenberg PH, Parkin DP, Burgess LJ. Cortical lens opacities in the young patient-an indication for a lipogram? S Afr Med J 2001; 91:520-524.
35. Bialas MC, Routledge PA. Adverse effects of corticosteroids. Adverse Drug React Toxicol Rev 1998; 17:227-235.
36. Ajamian PC. Traumatic cataract. Optom Clin 1993; 3:49-56.
37. Seifart HI, Gent WL, Parkin DP, van Jaarsveld PP, Donald PR. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J Chromatogr B 1995; 674:269-275.
38. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988; 16:1215.
39. Nurse, GT, Weiner JS, Jenkins T. The Peoples of Southern Africa and their Affinities. Oxford: Clarendon Press, 1985.
40. Ncayiyana DJ. 'African' is a rainbow word. S Afr Med J 1997; 87:1 (Editorial).
41. Campbell DA, Schoenwald RD, Duffel MW, Berfknecht CF. Characterization of arylamine acetyltransferase in the rabbit eye. Invest Ophthalmol Vis Sci 1991; 32:2190-2200.
42. Gaudet SJ, Razavi P, Caiafa GJ, Chader GJ. Identification of arylamine N-acetyltransferase activity in the bovine lens. Curr Eye Res 1995; 14:873-877.
43. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9:511-544.
44. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985; 29:342-375.
45. Weber WW. The Acetylator Genes and Drug Response. Oxford: Oxford University Press Inc., 1987.
46. Smith CAD, Smith G, Wolf CR. Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 1994; 30:1921-1935.
47. West S, Munoz B, Schein OD, Vitale S, Maguire M, Taylor HR, Bressler NM, et al: Cigarette smoking and risk for progression of nuclear opacities. Arch Ophthalmol 1995; 113:1377-1380.
48. Paterson CA, Delamere NA. The lens: In: Hart WA (editor). Adler's Physiology of the Eye, 9th edition. London: Mosby, 1992.
49. Bron AJ, Tripathi RC, Tripathi BJ. The lens and zonules. In: Bron AJ, Tripathi RC, Tripathi BJ (editors) Wolff's Anatomy of the Eye and Orbit, 8th edition. London: Chapman & Hall, 1997.
50. Hoenders HJ, Bloemendal H. Aging of lens proteins. In: Bloemendal H (editor), Molecular and Cellular Biology of the Eye Lens. New York: John Wiley, 1981.
51. Augusteyn RC. Protein modification in cataract: possible oxidative mechanisms. In: Duncan C (editor). Mechanisms of Cataract Formation in the Human Lens. London: Academic Press, 1981.
52. Groenen PJTA, Merck KB, De Jong WW, Bloemendal H. Structure and modifications of the junior chaperone α-crystallin. Eur J Biochem 1994; 225:1-19.